SPONSOR
Shanghai Jiatan Pharmatech Co., Ltd
Total Trials
2
Recruiting
2
Phases
Phase 2
Shanghai Jiatan Pharmatech Co., Ltd is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including Gastric Type Adenocarcinoma (GAS) With STK11 Mutation, Solid Tumor.
The trial portfolio spans Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Shanghai Jiatan Pharmatech Co., Ltd
How many clinical trials has Shanghai Jiatan Pharmatech Co., Ltd sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by Shanghai Jiatan Pharmatech Co., Ltd, of which 2 are actively recruiting participants. These trials cover conditions including Gastric Type Adenocarcinoma (GAS) With STK11 Mutation, Solid Tumor. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Shanghai Jiatan Pharmatech Co., Ltd research focus on?
Shanghai Jiatan Pharmatech Co., Ltd clinical trials span Gastric Type Adenocarcinoma (GAS) With STK11 Mutation, Solid Tumor. The research pipeline includes Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Shanghai Jiatan Pharmatech Co., Ltd clinical trial?
To participate in a Shanghai Jiatan Pharmatech Co., Ltd trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Shanghai Jiatan Pharmatech Co., Ltd trials with current recruitment status updated daily.
Clinical Trials by Shanghai Jiatan Pharmatech Co., Ltd
NCT06124963 Phase 2
Recruiting
A Study of WX390 Combined With Toripalimab in Patients With Advanced Gastric-type Endocervical Adenocarcinoma With STK11 Mutations
Gastric Type Adenocarcinoma (GAS) With STK11 Mutation
NCT06117540 Phase 2
Recruiting
A Study of WX390 in Patients With Advanced Solid Tumors
Solid Tumor
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: July 2026 · Data Methodology